Actively Recruiting

Phase Not Applicable
Age: 40Years - 75Years
All Genders
NCT05717192

BENTO - Bronchoscopic Lung Volume Reduction in Severe Emphysema Using Thermoablation

Led by IHF GmbH - Institut für Herzinfarktforschung · Updated on 2025-08-24

224

Participants Needed

12

Research Sites

188 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Prospective, 2-arm, randomised (2:1), multicentre, open-label clinical trial in patients with severe emphysema. The intervention arm will be treated with Bronchoscopic lung volume reduction in severe emphysema using thermoablation.The interventional treatment (bronchoscopic lung volume reduction) is compared with the usual conservative standard therapy (GOLD guidelines).

CONDITIONS

Official Title

BENTO - Bronchoscopic Lung Volume Reduction in Severe Emphysema Using Thermoablation

Who Can Participate

Age: 40Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age between 40 and 75 years
  • Written informed consent provided
  • Severe emphysema with bilateral heterogeneous upper lobe disease in GOLD stage 3 or 4
  • High-resolution CT showing severe emphysema within 6 months prior to inclusion
  • Functional evidence of severe pulmonary hyperinflation
  • Post-bronchodilator FEV1 between 20% and less than 45%
  • Total lung capacity (TLC) equal or greater than 100%
  • Residual volume (RV) greater than 175%
  • Arterial blood gases with PaCO2 less than or equal to 50 mmHg and PaO2 greater than 50 mmHg on room air
  • Dyspnea score of 2 or higher on the Medical Research Council modified scale (mMRC)
  • Ability to walk more than 140 metres in 6 minutes
  • Exhaustion of conservative treatment options before intervention
  • Optimized medical therapy according to GOLD guidelines
  • Non-smoker for at least 6 months prior to inclusion
  • Completed pulmonary and geriatric rehabilitation within the last 4 years
  • Participation in regular physical activities beyond daily living
  • Mentally and physically able to participate in study procedures and visits
  • Indication confirmed by interdisciplinary case conference with specialists
Not Eligible

You will not qualify if you...

  • Any condition interfering with trial follow-up, bronchoscopy, or affecting trial outcomes
  • Diffusing capacity of the lungs for carbon monoxide (DLCO) less than 20%
  • Body mass index (BMI) less than 18 or greater than 32 kg/m2
  • Pulmonary hypertension with peak systolic PAP over 45 mmHg or mean PAP over 25 mmHg
  • Clinically significant bronchiectasis
  • Pneumothorax or pleural effusions in the last 6 months
  • Previous lung surgeries in target lobes, including transplantation, lung volume reduction, bullectomy, lobectomy, pneumonectomy, or pleurodesis
  • Respiratory infection or COPD exacerbation within the last 6 weeks
  • Unstable COPD indicated by more than 3 hospitalizations requiring antibiotics in the past year, hospital stay in last 3 months, or daily use of systemic steroids over 5 mg prednisolone
  • Single large bulla greater than one-third of lobe volume or paraseptal emphysema in target lobe
  • Coagulopathy or current anticoagulant use
  • Current or recent endobronchial valves, coils, or polymer/adhesive treatments in target lobe
  • Immune system disorders requiring immunosuppressants
  • Recent myocardial infarction or acute coronary syndrome within past year
  • Hospitalization for left heart failure in past year
  • Clinically leading asthma or alpha-1-antitrypsin deficiency
  • Known sensitivity to bronchoscopy medications
  • Life expectancy less than 12 months
  • Newly prescribed morphine derivatives within last 4 weeks
  • Pregnancy at time of inclusion

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 12 locations

1

Charité Campus Benjamin Franklin

Berlin, Germany, 13353

Actively Recruiting

2

Gemeinschaftskrankenhaus Havelhöhe gGmbH Klinik für Anthroposophische Medizin

Berlin, Germany, 14089

Actively Recruiting

3

Universitätsklinikum Bonn, Medizinische Klinik und Poliklinik II

Bonn, Germany, 53127

Not Yet Recruiting

4

Pneumologische Universitätsklinik Ruhrlandklinik

Essen, Germany, 4542329

Actively Recruiting

5

Universitätsklinikum Halle (Saale)

Halle, Germany, 06120

Actively Recruiting

6

Thoraxklinik University of Heidelberg

Heidelberg, Germany, 69126

Actively Recruiting

7

Lungenklinik Hemer

Hemer, Germany, 58675

Actively Recruiting

8

Lungenfachklinik Immenhausen

Immenhausen, Germany, 34376

Actively Recruiting

9

Asklepios Klinik Langen, Klinik für Innere Medizin III

Langen, Germany, 63225

Not Yet Recruiting

10

KlinKlinikuim Lüdenscheid, Klinik für Pneumologie, internistische Intensivmedizin, Infektiologie und Schlafmedizin

Lüdenscheid, Germany, 58515

Actively Recruiting

11

Thoraxzentrum Bezirk Unterfranken

Münnerstadt, Germany, 97702

Actively Recruiting

12

Helios Hanseklinikum Stralsund

Stralsund, Germany, 18435

Actively Recruiting

Loading map...

Research Team

F

Felix Herth, MD

CONTACT

L

Leschek Brachmann, Masters of Science

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here